Diagnosis
How finding the right partner can move a solution forward to be accessible
By Gloria Kolb, Co-Founder & CEO – Elitone
Just a couple of months after launching Elitone in the UK, we were delighted to become an approved supplier to the NHS in March this year, to provide Trusts throughout the UK with Elitone as a new solution for pelvic health and incontinence.
The NHS is the UK’s publicly funded healthcare system that provides care to all its residents, with the majority of services, including doctor and hospital appointments, treatments and stays, free at point of use for most people. It’s the NHS that would help women with pelvic floor and bladder incontinence issues, were they to seek medical help.
Privately paid solutions are also an option, but usually too expensive for most to access.
We recognise that it’s a great achievement to be an approved NHS supplier, especially because it’s well-known that getting new products into the NHS is very complicated; procurement often takes months or years and there are many complexities due to its vast size (the NHS is the biggest employer in Europe), numerous stakeholders, the need to adhere to strict regulations and the necessity to balance cost-effectiveness with patient needs.
To help us achieve our goal, we met a proactive procurement company, through an industry trade show, that believed in our product, and now Elitone is available with NHS through HealthTrust Europe, a British public sector procurement company contracted by Mid and South Essex NHS Foundation Trust.
From 1 March 2025, Elitone was available across every one of the 217 individual National Health Trusts in the UK, offering a home delivery service of the products to help women who suffer with stress urinary incontinence, alongside a prescription service.
In the competitive selection process, there were, rightly, many criteria to fulfil to be considered as a supplier, with effectiveness, regulatory approvals, ease of access and cost-effectiveness making up part of the necessary criteria.
Elitone’s decade of providing a revolutionary incontinence tech solution in the US, backed by years of research and clinical trials, as well as nine patents, positively contributed to HealthTrust choosing Elitone as a new solution.
HealthTrust also recognised that adding more support in the UK for incontinence into their framework would enable the company to offer women greater access to innovative, effective, non-invasive care options.
It took the insistence of women within the framework to ensure this new category was created.
In the UK, it can be difficult to enter the NHS as a supplier, so it is wonderful that procurement companies like HealthTrust exist to provide another avenue for access, as well as ease the navigation of the competitive process.
The success of their Trust is in part due to bringing in new and innovative products, so they are motivated to ensure successful applications.
Elitone is now available for all UK healthcare professionals to access through the HealthTrust Europe Continence Goods and Services 2024 framework, Framespan.
It’s exciting to know that the 12 million women in the UK that suffer can now access this first-of-its-kind support through the NHS, signalling major progress for women’s health.
What’s more, with urinary incontinence currently costing the NHS almost £2 billion every year, it will help contribute to cost savings for the healthcare sector.
Elitone launched in the UK in January this year, available through various British online suppliers, such as Pharmacy2U and Currys, but the real success story for us is making the solution available through the NHS, offering a new and effective solution, for which those who suffer won’t need to pay, as they can now access it via their doctor or consultant.
It’s reported that the average woman spends £600 every year on incontinence solutions in the UK if they don’t seek medical help, so with this new availability, those individuals can save too.
We are delighted that this new opportunity will bring the benefits of Elitone to women in the UK.
Likewise, in the US, we have participated in an equally rigorous process with the help of partners to be an approved Medicare supplier of incontinence treatments.
Medicare, also a government programme, understands the cost of incontinence and supports preventative and at-home treatments.
As we look to the future, we sincerely hope we will be able to take Elitone to even more countries worldwide with the right partners, to offer an effective treatment solution for healthcare settings to help individuals overcome an issue that negatively affects them on a daily basis.
Gloria Kolb is the CEO and co-founder of Elitone, the first non-invasive, FDA-cleared, wearable treatment for women with urinary incontinence.
Elitone’s accolades include winning Best New Product by My Face My Body, Sling Shot, CES’ Innovation Award among many others. As an inventor with 30+ patents and advocate for women’s health, Gloria has been featured in Forbes as a Top Scientist Driving Innovation in Women’s Health, TechRound’s Top Women in Tech, Boston’s “40 Under 40” and MIT Review’s “World’s Top Innovators under 35.”
She has engineering degrees from MIT and Stanford, and an Entrepreneurship MBA from Babson College.
Menopause is often absent from women’s electronic health records, a study of nearly 396,000 women has found.
Researchers found menopause appeared almost seven times more often in participant surveys than in electronic health records (EHRs).
The findings suggest important reproductive health information, including age at menopause, may often be missing from health records used for research.
Audrey Hendricks, associate professor of bioinformatics at CU Anschutz and the study’s principal investigator, said: “Ultimately, we cannot study what we do not measure. We cannot treat what we do not know.
“Menopause has enormous implications for women’s health, but if we don’t consistently capture when menopause occurs and other important reproductive health information, we limit our ability to understand how this transition affects disease risk and health outcomes.”
Researchers at the University of Colorado Anschutz analysed data from women taking part in the National Institutes of Health’s All of Us Research Program.
They compared menopause information reported by participants in surveys with menopause diagnoses recorded in their electronic health records.
Around 193,000 menopause observations were identified in survey data, compared with approximately 28,000 diagnoses in EHR data.
Menopause was documented in electronic health records for only about 7 per cent of women in the dataset.
Nearly all participants with a menopause diagnosis recorded in their EHR also reported menopause in survey data. However, substantially fewer women had menopause documented in their health records.
Other important information was also frequently unavailable, including age at menopause, which researchers may use when examining links between menopause and chronic disease risk.
Menopause is a physiological transition that can affect cardiometabolic health and many other aspects of women’s health.
Researchers said relatively little is known about how factors including the timing and type of menopause influence health outcomes across diverse populations.
Large-scale programmes such as All of Us combine participant surveys, electronic health records and genomic data, but menopause-related research depends on relevant reproductive health information being available.
Missing menopause information can make it harder to investigate how the transition relates to health and disease.
The findings may also help researchers using All of Us data define menopause-related study populations, design studies and estimate how many participants are needed.
Hendricks said: “We have an enormous opportunity to use large-scale datasets to understand women’s health across the menopause transition and to identify who may be at greater risk for disease.
“But we need to make sure that the information researchers need is actually being collected.
“We must do a better job of capturing women’s health information, including reproductive health and measures related to menopause.”
Researchers said more complete and consistent collection of menopause and reproductive health information could help future studies examine factors such as age at menopause and their relationship with disease risk and health outcomes.
The FDA has granted accelerated approval to AstraZeneca drug Etcamah for certain adults with advanced breast cancer carrying an ESR1 mutation.
Etcamah, also known as camizestrant, was approved in combination with a CDK4/6 inhibitor, either abemaciclib, palbociclib or ribociclib.
The treatment is for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer when an estrogen receptor-1 (ESR1) mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy using an FDA-authorised test.
ESR1 mutations are acquired resistance mutations that tumours may develop during treatment with aromatase inhibitors, a type of endocrine therapy commonly used as a front-line treatment for locally advanced or metastatic breast cancer.
Fewer than 5 per cent of patients have the mutation when HR-positive metastatic breast cancer is diagnosed, according to the FDA. After disease progression on an aromatase inhibitor, nearly 40 per cent have the mutation.
Acting FDA commissioner Kyle Diamantas said: “Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment.
“We owe them every weapon in our arsenal.
“Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses.”
The accelerated approval programme allows earlier approval of drugs that treat serious conditions and fill an unmet medical need based on surrogate or intermediate endpoints.
For Etcamah, approval was based on how long patients lived without their disease worsening, measured from when the resistance mutation was first detected in their blood.
The FDA said it has not yet been confirmed whether intervening when the mutation is detected, rather than waiting until disease progression is confirmed, results in a clinically meaningful benefit. Confirmatory studies are therefore required to verify and describe clinical benefit.
Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said: “I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval.
“This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show that the disease is progressing.
“But additional evidence is needed to confirm clinical benefit.”
Circulating tumour DNA, or ctDNA, consists of small pieces of tumour DNA released into the blood and can allow earlier molecular detection of resistance mutations.
The FDA also authorised the Guardant360 CDx assay as a companion diagnostic to identify patients with breast cancer who have ESR1 mutations for treatment with camizestrant.
Efficacy was assessed in a clinical trial comparing a switch to Etcamah plus a CDK4/6 inhibitor with continued treatment using an aromatase inhibitor plus a CDK4/6 inhibitor.
Estimated median progression-free survival was 16 months in the Etcamah group, compared with 9.2 months in the aromatase inhibitor group.
Etcamah’s prescribing information includes a boxed warning about the risk of irregular heart rhythm when taken with certain other medicines. It also includes warnings about an abnormally slow heart rate and potential harm to an unborn baby.
The FDA convened its Oncologic Drugs Advisory Committee for the application on 30 April 2026.
Four leading cardiovascular health groups have agreed new guidance for healthcare professionals assessing patients with suspected heart attacks.
Historically, some less common forms of heart attack, which evidence shows affect women far more than men, have been classified as less important, with treatment and care often worse as a result.
Experts said women had been receiving less effective treatments that did not always target the specific cause of their heart attack and could even make them more unwell.
The changes were announced in Munich on the opening day of the annual congress of the European Society of Cardiology (ESC).
Professor Bryan Williams, chief scientific and medical officer of the British Heart Foundation, said: “This is a landmark moment, a radical shift in how we define and diagnose heart attacks worldwide which will transform people’s care.
“For decades, women have missed out on accurate diagnoses and treatment.
“This focus on finding less common causes of heart attacks, which predominantly affect women, should help to change that. It could be life-changing for huge numbers of women in the UK and worldwide.”
The new guidance upgrades three types of heart attack that can be up to 10 times more common in women and are often caused by childbirth, exercise and emotional stress.
The most serious cases, previously known as “type 1” and now classed as “primary” heart attacks, had previously prioritised those caused by a clot blocking blood flow to the heart.
Other forms can involve reduced blood flow for different reasons, including the tightening or tearing of coronary arteries. These can be more likely to be missed or treated less urgently.
The guidance also introduces a lower diagnostic threshold for women based on levels of troponin, a protein released into the blood when the heart is injured and damaged.
Previously, women were expected to meet the same troponin threshold as men to receive a diagnosis.
Williams said the streamlined heart attack categories would also help patients understand the cause of their heart attack and what comes next.
The three upgraded types are coronary artery spasm, coronary embolism and spontaneous coronary artery dissection (SCAD).
Coronary artery spasm involves the tightening of an artery, which can deprive the heart muscle of blood and oxygen. It can be caused by emotional stress, exercise or extreme cold.
Coronary embolism occurs when a blood clot or fatty deposit travels to a coronary artery and causes a blockage.
SCAD is caused by a tear in a coronary artery. Around 80 per cent of cases occur in women, and it often happens during or soon after pregnancy.
Professor Nicholas Mills, a cardiologist at the University of Edinburgh who led the international taskforce behind the guidance, said it was “the first time that we’ve had a truly global approach to aligning how we diagnose what is probably the most important diagnosis there is”.
He said: “It kills so many people, and we’ve never got everyone together around the world to agree how we’re going to describe it, classify it, explain it to our patients.
“Our job now is to implement this as widely as possible. It’s just as relevant for the UK as it is for any other country around the world. It is a revolution. It’s going to make care better for patients.”
Mills said there had been “unintended systematic bias against women”, including through the use of the key blood test for diagnosing heart attacks at an average level, which picks up all men but misses some women.
He said: “This is used for all types of heart attack in every emergency department in the world, and we want to make sure that it’s used correctly.”
The guidance was drawn up by the ESC, the American College of Cardiology, the American Heart Association and the World Heart Federation.
Entrepreneur2 weeks agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Pregnancy2 weeks agoUK study aims to transform maternity care for high-risk pregnancies
Pregnancy3 days agoParacetamol use may impact future fertility, studies suggest
Sponsored Content6 days agoLast chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September
Menopause1 week agoMenopause hormone treatment may ease brain fog, study suggests
Menopause5 days agoCancer drug could tackle osteoporosis menopause weight gain
News2 weeks agoSpanish agency criticised for menopause guidelines based on male studies
Cancer2 weeks agoNHS IVF access review launched in Scotland